JP2022191405A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022191405A5 JP2022191405A5 JP2022165113A JP2022165113A JP2022191405A5 JP 2022191405 A5 JP2022191405 A5 JP 2022191405A5 JP 2022165113 A JP2022165113 A JP 2022165113A JP 2022165113 A JP2022165113 A JP 2022165113A JP 2022191405 A5 JP2022191405 A5 JP 2022191405A5
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- dosage
- antipruritic agent
- noon
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003908 antipruritic agent Substances 0.000 claims 31
- 208000003251 Pruritus Diseases 0.000 claims 19
- 230000007803 itching Effects 0.000 claims 10
- 230000003902 lesion Effects 0.000 claims 9
- YZLZPSJXMWGIFH-BCXQGASESA-N nalbuphine hydrochloride Chemical compound [H+].[Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 YZLZPSJXMWGIFH-BCXQGASESA-N 0.000 claims 8
- 206010037083 Prurigo Diseases 0.000 claims 7
- 150000002148 esters Chemical class 0.000 claims 6
- 229960000805 nalbuphine Drugs 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000006186 oral dosage form Substances 0.000 claims 5
- 238000013268 sustained release Methods 0.000 claims 5
- 239000012730 sustained-release form Substances 0.000 claims 5
- 229920000161 Locust bean gum Polymers 0.000 claims 4
- 239000000711 locust bean gum Substances 0.000 claims 4
- 235000010420 locust bean gum Nutrition 0.000 claims 4
- 208000035874 Excoriation Diseases 0.000 claims 3
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical group O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 150000002433 hydrophilic molecules Chemical class 0.000 claims 3
- 239000000230 xanthan gum Substances 0.000 claims 3
- 235000010493 xanthan gum Nutrition 0.000 claims 3
- 229920001285 xanthan gum Polymers 0.000 claims 3
- 229940082509 xanthan gum Drugs 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 201000009053 Neurodermatitis Diseases 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229960001513 nalbuphine hydrochloride Drugs 0.000 claims 2
- 208000017940 prurigo nodularis Diseases 0.000 claims 2
- 239000004971 Cross linker Substances 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 206010025421 Macule Diseases 0.000 claims 1
- 206010054107 Nodule Diseases 0.000 claims 1
- 206010033733 Papule Diseases 0.000 claims 1
- 239000003431 cross linking reagent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 230000001823 pruritic effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000004448 titration Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662412578P | 2016-10-25 | 2016-10-25 | |
| US62/412,578 | 2016-10-25 | ||
| JP2019543196A JP2019532112A (ja) | 2016-10-25 | 2017-10-25 | 結節性痒疹の治療方法 |
| PCT/US2017/058294 WO2018081273A1 (en) | 2016-10-25 | 2017-10-25 | Treatment of prurigo nodularis |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543196A Division JP2019532112A (ja) | 2016-10-25 | 2017-10-25 | 結節性痒疹の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022191405A JP2022191405A (ja) | 2022-12-27 |
| JP2022191405A5 true JP2022191405A5 (https=) | 2023-01-10 |
Family
ID=62025443
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543196A Pending JP2019532112A (ja) | 2016-10-25 | 2017-10-25 | 結節性痒疹の治療方法 |
| JP2022165113A Pending JP2022191405A (ja) | 2016-10-25 | 2022-10-14 | 結節性痒疹を治療するための抗掻痒剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543196A Pending JP2019532112A (ja) | 2016-10-25 | 2017-10-25 | 結節性痒疹の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20180125840A1 (https=) |
| EP (1) | EP3532061A4 (https=) |
| JP (2) | JP2019532112A (https=) |
| KR (1) | KR102696347B1 (https=) |
| CN (1) | CN109862895A (https=) |
| AU (1) | AU2017350852A1 (https=) |
| BR (1) | BR112019008241A2 (https=) |
| CA (1) | CA3038544A1 (https=) |
| MX (1) | MX2019004804A (https=) |
| NZ (1) | NZ751972A (https=) |
| WO (1) | WO2018081273A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112672743A (zh) * | 2018-07-11 | 2021-04-16 | 特雷维治疗股份有限公司 | 肝病瘙痒症状的治疗 |
| IL318587A (en) | 2018-07-23 | 2025-03-01 | Trevi Therapeutics Inc | Treatment of chronic cough, shortness of breath and wheezing |
| IL294601A (en) * | 2020-01-10 | 2022-09-01 | Trevi Therapeutics Inc | Methods of administration of nalbuphine |
| US12508259B2 (en) | 2022-02-01 | 2025-12-30 | HUMANWELL PHARMACEUTICAL US, Inc. | Pharmaceutical formulations containing Nalbuphine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005537298A (ja) * | 2002-08-02 | 2005-12-08 | ペンウェスト ファーマシューティカルズ カンパニー | メトホルミンの徐放性製剤 |
| JP2005162736A (ja) * | 2003-11-10 | 2005-06-23 | Astellas Pharma Inc | 徐放性医薬組成物 |
| AU2004299077A1 (en) * | 2003-12-12 | 2005-06-30 | Penwest Pharmaceuticals Co. | Sustained release torsemide dosage forms |
| EP1931315B1 (en) * | 2005-08-24 | 2013-10-16 | Penwest Pharmaceuticals Co. | Sustained release formulations of nalbuphine |
| WO2009097463A1 (en) * | 2008-01-29 | 2009-08-06 | Superdimension, Ltd. | Target identification tool for intra body localization |
| KR20220044385A (ko) * | 2012-12-14 | 2022-04-07 | 트레비 테라퓨틱스, 인코포레이티드 | 소양증을 치료하는 방법 |
| US8987289B2 (en) * | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| WO2015192071A1 (en) * | 2014-06-13 | 2015-12-17 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| US20170216277A1 (en) * | 2016-01-06 | 2017-08-03 | Trevi Therapeutics, Inc. | Therapeutic use of nalbuphine without aquaretic effects |
| CN105560202B (zh) * | 2016-03-11 | 2019-05-24 | 广州玻思韬控释药业有限公司 | 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用 |
-
2017
- 2017-10-25 MX MX2019004804A patent/MX2019004804A/es unknown
- 2017-10-25 EP EP17863420.0A patent/EP3532061A4/en not_active Withdrawn
- 2017-10-25 CA CA3038544A patent/CA3038544A1/en active Pending
- 2017-10-25 US US15/793,153 patent/US20180125840A1/en not_active Abandoned
- 2017-10-25 AU AU2017350852A patent/AU2017350852A1/en not_active Abandoned
- 2017-10-25 WO PCT/US2017/058294 patent/WO2018081273A1/en not_active Ceased
- 2017-10-25 JP JP2019543196A patent/JP2019532112A/ja active Pending
- 2017-10-25 KR KR1020197011730A patent/KR102696347B1/ko active Active
- 2017-10-25 BR BR112019008241A patent/BR112019008241A2/pt not_active Application Discontinuation
- 2017-10-25 NZ NZ751972A patent/NZ751972A/en unknown
- 2017-10-25 CN CN201780065280.6A patent/CN109862895A/zh active Pending
-
2021
- 2021-12-08 US US17/545,487 patent/US20220347171A1/en not_active Abandoned
-
2022
- 2022-10-14 JP JP2022165113A patent/JP2022191405A/ja active Pending
-
2023
- 2023-06-27 US US18/342,395 patent/US20230338367A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022191405A5 (https=) | ||
| AU2018357775B2 (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD) | |
| US20040023840A1 (en) | Combination of organic compounds | |
| JP2021526138A5 (https=) | ||
| CA2972379A1 (en) | Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers | |
| US20060004076A1 (en) | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation | |
| JP2022191405A (ja) | 結節性痒疹を治療するための抗掻痒剤 | |
| JP2021169534A5 (https=) | ||
| JP5514123B2 (ja) | 卵巣癌を治療するための、パクリタキセルを含む配合剤 | |
| AU2022404695A1 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| JP2019532112A5 (ja) | 結節性痒疹を治療するための抗掻痒剤 | |
| JP2021514380A5 (ja) | 筋障害及び骨障害を処置するための化合物及び組成物 | |
| KR102843222B1 (ko) | 마이크로조말 트리글리세라이드 전달 단백질 억제제의 섬유화 질환 치료 용도 | |
| CN100506224C (zh) | 包含选择性环加氧酶-2抑制剂的组合 | |
| JP2019509309A5 (https=) | ||
| Samborski et al. | Intra‐articular treatment of arthritides and activated osteoarthritis with the 5‐HT3 receptor antagonist tropisetron. A double‐blind study compared with methylprednisolone | |
| KR20240121251A (ko) | 진행성 섬유화 간질성 폐 질환의 치료를 위한 신규한 경구 약제학적 조성물 및 투여 섭생 | |
| EP1420782B1 (en) | Use of nefiracetam for treating post-stroke neurodegeneration | |
| JP6940279B2 (ja) | 注腸剤 | |
| JP2011502112A (ja) | 抗ガン治療の副作用を治療するための新規組成物 | |
| JP2003523385A (ja) | 神経変性疾患の治療法 | |
| TW201806599A (zh) | 用於快速開始抗抑鬱作用之給藥方案 | |
| EP1670481B1 (en) | Use of ciclesonide for the treatment of inflammatory bowel diseases | |
| JP2022521444A (ja) | 直腸および局所投与のためのゲル | |
| JP2005519918A5 (https=) |